{"title":"萨妥珠单抗替鲁莫替康可改善mTNBC的OS","authors":"David Killock","doi":"10.1038/s41571-025-01022-0","DOIUrl":null,"url":null,"abstract":"<p>Patients with progression of metastatic triple-negative breast cancer (mTNBC) following first-line treatment have a dismal prognosis. The TROP2-directed antibody–drug conjugate (ADC) sacituzumab govitecan improves outcomes in this setting. New data from the phase III OptiTROP-Breast01 trial support sacituzumab tirumotecan (sac-TMT), a different anti-TROP2 ADC with a linker designed for improved bioactivity, as another treatment option for such patients.</p><p>In this trial performed in China, 263 patients with mTNBC who had received ≥2 prior lines of therapy, including at least one for metastatic disease, were randomly assigned 1:1 to receive sac-TMT or physician’s choice of standard single-agent chemotherapy. The primary end point was progression-free survival (PFS).</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"43 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sacituzumab tirumotecan improves OS in mTNBC\",\"authors\":\"David Killock\",\"doi\":\"10.1038/s41571-025-01022-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients with progression of metastatic triple-negative breast cancer (mTNBC) following first-line treatment have a dismal prognosis. The TROP2-directed antibody–drug conjugate (ADC) sacituzumab govitecan improves outcomes in this setting. New data from the phase III OptiTROP-Breast01 trial support sacituzumab tirumotecan (sac-TMT), a different anti-TROP2 ADC with a linker designed for improved bioactivity, as another treatment option for such patients.</p><p>In this trial performed in China, 263 patients with mTNBC who had received ≥2 prior lines of therapy, including at least one for metastatic disease, were randomly assigned 1:1 to receive sac-TMT or physician’s choice of standard single-agent chemotherapy. The primary end point was progression-free survival (PFS).</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01022-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01022-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Patients with progression of metastatic triple-negative breast cancer (mTNBC) following first-line treatment have a dismal prognosis. The TROP2-directed antibody–drug conjugate (ADC) sacituzumab govitecan improves outcomes in this setting. New data from the phase III OptiTROP-Breast01 trial support sacituzumab tirumotecan (sac-TMT), a different anti-TROP2 ADC with a linker designed for improved bioactivity, as another treatment option for such patients.
In this trial performed in China, 263 patients with mTNBC who had received ≥2 prior lines of therapy, including at least one for metastatic disease, were randomly assigned 1:1 to receive sac-TMT or physician’s choice of standard single-agent chemotherapy. The primary end point was progression-free survival (PFS).
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
